Figure 2:
Figure 2:. A: Time to tumor progression (TTP, N=104) and B: overall survival (OS) of patients not achieving a CR with 4 courses of rituximab (N=72) in the ST and RSST treatment approach

A: Time to tumor progression (TTP, N=104) and B: overall survival (OS) of patients not achieving a CR with 4 courses of rituximab (N=72) in the ST and RSST treatment approach

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal